Author Archives: admin

Top Growth Stocks To Invest In Right Now

COB and CEO of Facebook Inc (NASDAQ:FB) Mark Zuckerberg sold 247,452 shares of FB on 09/20/2017 at an average price of $171.75 a share. The total sale was $42.5 million.

Facebook Inc is the world’s largest online social network. Its products are Facebook, Instagram, Messenger, WhatsApp, and Oculus. Its products enable people to connect and share through mobile devices and personal computers. Facebook Inc has a market cap of $496.94 billion; its shares were traded at around $171.11 with a P/E ratio of 37.05 and P/S ratio of 15.23. Facebook Inc had annual average EBITDA growth of 40.60% over the past five years.

CEO Recent Trades:

COB and CEO, 10% Owner Mark Zuckerberg sold 247,452 shares of FB stock on 09/20/2017 at the average price of $171.75. The price of the stock has decreased by 0.37% since.COB and CEO, 10% Owner Mark Zuckerberg sold 247,147 shares of FB stock on 09/08/2017 at the average price of $171.96. The price of the stock has decreased by 0.49% since.COB and CEO, 10% Owner Mark Zuckerberg sold 254,525 shares of FB stock on 08/28/2017 at the average price of $166.97. The price of the stock has increased by 2.48% since.

Directors and Officers Recent Trades:

Top Growth Stocks To Invest In Right Now: Nordstrom Inc.(JWN)

Advisors’ Opinion:

  • [By Shanthi Rexaline]

    Here are the number of stores at the end of the third quarter of 2016 compared to the number of stores in 2007:

    J C Penney Company Inc (NYSE: JCP): 1,014 vs. 1,067. Kohl’s Corporation (NYSE: KSS): 1,155 vs. 929. Macy’s Inc (NYSE: M): 880 vs. 853. Nordstrom, Inc. (NYSE: JWN): 348 vs. 157. TJX Companies Inc (NYSE: TJX): 582 vs. 2,500. Wal-Mart Stores Inc (NYSE: WMT)*: 4,574 vs. 4,141.

    Source: SEC Filings


    There seems to be no cure for the rise of e-commerce, Cramer admitted to viewers, as a vicious downgrade of Nordstrom (JWN) last week sent shares reeling by more than 9%.

  • [By Chris Lange]

    Nordstrom, Inc. (NYSE: JWN) reported fiscal first-quarter financial results after markets closed Thursday. The company reported $0.43 in earnings per share (EPS) and $3.3 billion in revenue versus consensus estimates from Thomson Reuters that called for $0.27 in EPS and $3.34 billion in revenue. The same period from last year had $0.26 in EPS and $3.25 billion in revenue.

  • [By Jeremy Bowman]

    Downbeat holiday sales reports byKohl’s(NYSE:KSS) andMacy’s(NYSE:M) pushed the department store sector, and much of retail, in the red on Thursday. As of 11:38 a.m. EST, Kohl’s was down 19.5%, Macy’s was down 14.4%, and peers includingNordstrom(NYSE: JWN) andJ.C. Penney(NYSE: JCP) also tumbled, falling 9.8% and 6.7%, respectively.


    * The market bent yesterday but today it stabilized. (A good showing, all things being considered–but in no way decisive going forward).
    * Gold +$5/oz.
    * Crude oil +$0.50 and the rise is taking up some energy stocks.
    * The Russell returned to the spotlight.
    * Life insurance–particularly Lincoln National (LNC) (on an upgrade). Hartford Financial Services (HIG) gets a small lift.
    * Retail returned from the depths. The standouts–L Brands (LB) , Kohl’s (KSS) , Bed Bath (BBBY) , Nordstrom (JWN) and Gap (GPS) .
    * Ag equipment–after an analyst upgrade yesterday.
    * Brokerages.
    * Homebuilders catch a bid.
    * Day one of the Masters Golf Tournament.

Top Growth Stocks To Invest In Right Now: MEDIFAST INC(MED)

Advisors’ Opinion:

  • [By Lee Jackson]

    These companies also reported insider buying last week: Carrizo Oil and Gas Inc. (NASDAQ: CRZO), Medifast Inc. (NYSE: MED), Medley Capital Corp. (NYSE: MCC), Occidental Petroleum Corp. (NYSE: OXY) and Sothebys (NYSE: BID).

  • [By Peter Graham]

    A long term performance chart shows small cap weight loss or dieting stocks Weight Watchers International and Reliv International, Inc (NASDAQ: RELV) still underperforming whileNutriSystem Inc (NASDAQ: NTRI) and Medifast Inc (NYSE: MED) began taking off early last year:

  • [By Peter Graham]

    Although obesity is widespread, small cap dieting stocks havetended to causeinvestor portfolios to loose weight. A long term performance chart shows small cap weight loss or dieting stocks Weight Watchers International and Reliv International, Inc (NASDAQ: RELV) stillbelow or at breakeven for longer term investors whileMedifast Inc (NYSE: MED)has performed better and NutriSystem Inc (NASDAQ: NTRI) hasfinally begun to take offearly last year:

  • [By Lisa Levin]

    In trading on Friday, non-cyclical consumer goods & services shares rose by just 0.3 percent. Meanwhile, top losers in the sector included Medifast Inc (NYSE: MED), down 5 percent, and Bridgford Foods Corporation (NASDAQ: BRID), down 6 percent.

Top Growth Stocks To Invest In Right Now: Intuitive Surgical Inc.(ISRG)

Advisors’ Opinion:

  • [By Joseph Hogue]

    Enter Intuitive Surgical (Nasdaq: ISRG) and Da Vinci, a robotic arm that allows surgeons to operate with just a single incision less than an inch in size.

  • [By Demitrios Kalogeropoulos]

    As for individual stocks, IBM (NYSE:IBM) and Intuitive Surgical (NASDAQ:ISRG) attracted heavy investor interest following their quarterly earnings releases.

  • [By Benzinga News Desk]

    Microsoft (NASDAQ: MSFT) Reports Q4 EPS $0.69 vs. Est. $0.58, Rev. $22.64B vs. Est. $22.14B
    Intuitive Surgical (NASDAQ: ISRG) Reports Q2 GAAP EPS $4.71, Adj. EPS $5.62 vs $4.97 Est., Sales $670.1M vs $540.7M Est.
    Halliburton (NYSE: HAL) Q2 EPS ($0.14) vs ($0.19) est, Revenue $3.84B vs $3.75B est
    Morgan Stanley (NYSE: MS) Q2 EPS $0.75 vs $0.59 est, Revenue $8.9B vs $8.3B est

Top Growth Stocks To Invest In Right Now: Buffalo Wild Wings Inc.(BWLD)

Advisors’ Opinion:

  • [By Peter Graham]

    A long term performance chart shows Dave & Busters Entertainment doubling in valuewhile potential peer, small cap upscale gentlemen’s clubs and restaurant ownerRCI Hospitality Holdings, Inc (NASDAQ: RICK), began to takeoff last yearand small capBuffalo Wild Wings (NASDAQ: BWLD) has basically been range bound for the last four days:

  • [By Peter Graham]

    After the market closed yesterday, small cap restaurant and entertainment stockDave & Busters Entertainment Inc (NASDAQ: PLAY) reported Q4 2016 earnings with shares falling by mid single digit percentagesin after hours trading. The Company apparently beat expectations on earnings, but fell short of expectations for comps. Likewise, the stock has already had a very good run meaning expectations were super high.Take a look at the following long term chart which shows Dave & Busters Entertainmentsshare performanceascompared to potential peers such as Buffalo Wild Wings (NASDAQ: BWLD) and upscale gentlemen’s clubs and restaurant ownerRCI Hospitality Holdings, Inc (NASDAQ: RICK):

  • [By Lisa Levin]

    Buffalo Wild Wings (NASDAQ: BWLD) shares were also up, gaining 20 percent to $121.75 after the company posted better-than-expected earnings for its third quarter and raised its forecast for the full year.

This Cannabidiol Beverage Small Cap Could Make Investors High

Many people may not realizeexactly what cannabinoids inCannabis are and the fact that there are actually 113 active cannabinoid compounds in the plant. Its these compounds that alter neurotransmitter release in the brainwith the most notableof these compounds beingphytocannabinoid tetrahydrocannabinol (THC) -the primary psychoactive compound in the plant.

Cannabidiol (CBD) on the other hand accounts forup to 40% of the Cannabis plant’s extract. However andwhile Cannabidiol itself would bea cannabis compound that may have significant medical benefits, it does not make people feel stoned as its is non-psychoactive compound. This makes CBD anappealing option for relief frominflammation,pain,anxiety,psychosis,seizures, spasms andother conditionswithout feelings of lethargy ordysphoria. Scientific and clinical research suggests that CBDhas potential as a treatment for a wide range of conditions, including arthritis, diabetes, alcoholism, MS, chronic pain, schizophrenia, PTSD,depression,antibiotic-resistant infections,epilepsy and other neurological disorders.

That leads me to small cap Gridiron BioNutrients, formerly MyCloudz, Inc (OTC: MYYZ) ianutraceutical innovator specializing in Cannabidiol health health and wellness products that was founded by Darren Long, a former NFL tight-end and 3x All American College Football Player who became an advocate of health and proper nutrition as a result of the symptoms from Chronic Traumatic Encephalopathy (CTE) or brain concussions. Gridiron BioNutrients current innovative CBD products include Gridiron MVP water, Gridiron MVP concentrate, Gridiron CBD H2O Probiotics water, Gridiron Premium Hemp Salve, Gridiron Premium Hemp Oil and Gridiron Premium Hemp Oil Capsules.

Right now, Gridiron BioNutrients unique flagship product would be Gridiron MVP water and concentrate- an innovative formulation that delivers Humic and Fulvic minerals, Probiotics, Electrolytes, 77+ trace minerals and Premium Nano CBD with a pH of 10. The Company plans to roll-out additional products over the next twelve months.

A couple of weeks ago, Gridiron BioNutrients announced the execution of a Three Year Endorsement Agreement with the National Football League Alumni effectiveNovember 1, 2017throughNovember 2, 2020. The NFLA or NFL Alumni is comprised of former NFL players, coaches, staffers, cheerleaders, spouses and associate members whose mission is to serve, assist and inform former players and their families by offering a varietymedical, financial and social programs to help members lead healthy, productive and connected lives (Pro Football Legends is the commercial marketing arm of the NFL Alumni). CEO Darren Long had this to say in the announcement:

Being a NFL alumnus myself, I am confident this Agreement with the NFLA will provide Gridiron a unique advantage to promote and advertise Gridiron licensed productsin partnership with the NFLA. In addition, we are thrilled with the opportunity to work with the NFL Alumni in developing new innovative nutritional products, supported by science,through our health and wellness program that will be tailored to specific needs ranging from Chronic Traumatic Encephalopathy CTE to daily nutritional supplementation.

The Companys marketing plan calls for working closing with both amateur and professional sports teams as the founders background puts himin a position to understand the unique circumstances various athletes face in maintaining a healthy lifestyle both on and off the field.

Best Bank Stocks To Watch Right Now

Like most other industries, the banking industry has seen its fair share of fluctuations in recent years. Between the recession, the subsequent economic recovery and the introduction of new financial technologies, the way people manage their money has shifted dramatically – and that’s not about to stop anytime soon.

Big disruptions – many of them driven by technology – are poised to rock the banking industry in the very near future. Below, seven Forbes Finance Council members share predictions for changes happening in the next five years.

Clockwise from left: Crystal Stranger, John Perry, Ismael Wrixen,Ivan Illan, Nick Stamos, Charlie Youakim, René Lacerte. All photos courtesy of individual members.

1. Paper Checks Will No Longer Be Used

Best Bank Stocks To Watch Right Now: Euronet Worldwide Inc.(EEFT)

Advisors’ Opinion:

  • [By Peter Graham]

    Small cap Blackhawk Network Holdingshas movedboth sidewaysor slowly upward after its IPO spinoff from Safeway (NYSE: SWY) whilepotential peer of Green Dot Corporation (NYSE: GDOT) is performing betterwhile Euronet Worldwide, Inc (NASDAQ: EEFT) has been a outperformer:

  • [By Ben Levisohn]

    Western Union (WU) soared to the top of the S&P 500 today after MoneyGram International (MGI) received a bid from Euronet Worldwide (EEFT).

    Agence France-Presse/Getty Images

    Shares of Western Union gained 3.5% to $20.27 today, while the S&P 500 fell 0.3% to 2,365.45.MoneyGram International surged 25% to $15.77, while Euronet Worldwide advanced 0.3% to $83.22.

  • [By Peter Graham]

    Blackhawk Network Holdingshas largelymovedsidewaysor slowly upward after its IPO spinoff from Safeway (NYSE: SWY) whilepotential peers like small capGreen Dot Corporation (NYSE: GDOT) and mid capEuronet Worldwide, Inc (NASDAQ: EEFT) have beenoutperformers:

Best Bank Stocks To Watch Right Now: Lam Research Corporation(LRCX)

Advisors’ Opinion:


    The same case is made for Action Alerts PLUS holding Alphabet (GOOGL) and for Lam Research (LRCX) and Broadcom (AVGO) and Growth Seeker holding Amazon (AMZN) –and a host of other high-growth companies.


    Lam Research (LRCX) has consistently outgrown the overall semiconductor-equipment market due to its high exposure to 3D NAND flash memory.

    Demand for wafer-fabrication equipment is notoriously volatile. However, over the last 90 days, the consensus profit estimate for this year jumped 17%, with 95% of analysts raising their targets.

  • [By Ben Levisohn]

    Lam Research (LRCX) soared to the top of the S&P 500 today after beating earnings forecasts and raising its fourth-quarter guidance.

    Getty Images

    Lam Researchgained 6.9% to $136.17 today, while the S&P 500 declined 0.2% to 2,338.17.

    Credit Suisse analysts Farhan Ahmad and John Pitzer and argues that Lam Research’s “new trough is higher than [its] old peak.” They explain:

    We expect that bears will continue to argue that CY17 is a “Peak” year; however we think that investors are missing that it now costs >2x more to get incremental bit growth than three years ago. It is noteworthy that despite ~$17bn of memory WFE in 2016 both NAND and DRAM markets went from oversupply to undersupply – implying that new trough for memory investments is even higher than old peak (2010 memory peak had WFE of $12.6bn). We view Semi Growth, rising capital intensity, and growing China CapEx as secular multiyear themes, which could continue to provide growth in coming years. In addition, in case of tax reform there could be potential to return >$50 per share to shareholders by 2020…Increase TP to $160 (from $143), based on 12x of CY18 EPS plus net cash adj for taxes.

    Lam Research’s market capitalization rose to $22.2 billion today from $20.8 billion yesterday.

  • [By Dan Caplinger]

    Wednesday was a mixed day for the stock market, as the Dow Jones Industrials dropped by triple digits but other major benchmarks fared much better. Crude oil prices fell nearly $2 per barrel to $50.50, and that hurt energy companies, along with a poor earnings report from technology giant IBM. Yet the broader market held up better, and the Nasdaq Composite actually gained ground. In particular, some good news from a few individual companies helped hold the markets up, and CalAmp (NASDAQ:CAMP), Lithia Motors (NYSE:LAD), and Lam Research (NASDAQ:LRCX) were among the best performers on the day. Below, we’ll look more closely at these stocks to tell you why they did so well.

Best Bank Stocks To Watch Right Now: WGL Holdings Inc(WGL)

Advisors’ Opinion:

  • [By Shauna O’Brien]

    Brean Capital reported on Friday that it has upgraded natural gas utility company WGL Holdings Inc (WGL).

    The firm has raised its rating on WGL from “Hold” to “Buy,” and has given the company a $46 price target. This price target suggests a 12% increase from the stock’s current price of $40.62. The upgrade was primarily based on valuation and future investment opportunities.

    “Like many utilities in the gas LDC space, the shares of WGL Holdings have come off recent highs and are now trading at a level we consider attractive,” analyst Michael Gaugler comments. “Beyond valuation, we consider the recent announcement of conditional approval of Dominion’s Cove Point facility for LNG export as a positive development in terms of future investment opportunities, given the company’s one-third interest in the Commonwealth Pipeline project, which we believe will be revisited due to future increased demand.”

    WGL Holdings shares were mostly flat during pre-market trading Friday. The stock has been mostly flat YTD.

Best Bank Stocks To Watch Right Now: CyberArk Software Ltd.(CYBR)

Advisors’ Opinion:

  • [By Joe Tenebruso]

    CyberArk Software (NASDAQ:CYBR) reported fourth-quarter financial results on Feb. 9. The Israeli cybersecurity specialist continues to win new business for its “privileged account” security solutions, which help to protect against cyberattacks that use insider privileges to penetrate network perimeters and assault the most sensitive areas of an enterprise’s IT infrastructure.

  • [By Lisa Levin]

    Some of the stocks that may grab investor focus today are:

    Wall Street expects Citigroup Inc (NYSE: C) to report quarterly earnings at $1.26 per share on revenue of $17.71 billion before the opening bell. Citigroup shares rose 0.30 percent to $67.22 in after-hours trading.
    Analysts are expecting JPMorgan Chase & Co. (NYSE: JPM) to have earned $1.65 per share on revenue of $25.61 billion in the latest quarter. JPMorgan will release earnings before the markets open. JPMorgan shares gained 0.48 percent to $93.55 in after-hours trading.
    Cyberark Software Ltd (NASDAQ: CYBR) lowered its guidance for the second quarter. The company now expects total revenue of $57.0 million to $57.5 million, versus earlier guidance of $61.0 million to $62.0 million. Cyberark shares dipped 17.65 percent to $42.00 in the after-hours trading session.
    Before the opening bell, First Republic Bank (NYSE: FRC) is projected to report quarterly earnings at $1.1 per share on revenue of $675.70 million. First Republic Bank shares dropped 0.80 percent to close at $101.35 on Thursday.

    Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

Best Bank Stocks To Watch Right Now: Veeva Systems Inc.(VEEV)

Advisors’ Opinion:

  • [By Brian Stoffel]

    To say that Veeva Systems (NYSE:VEEV) has performed well as a publicly traded company would be an understatement. While the stock itself is actually down since its post-IPO days, the company’s fundamentals have vastly improved during that time frame.

  • [By Brian Stoffel]

    Last week, management at Veeva Systems (NYSE:VEEV) reported earnings that investors have become accustomed to. In fact, shareholders have been downright spoiled: both the top and bottom lines came in ahead of expectations; annual sales growth from Veeva’s non-CRM division came in at a blistering 113%.

  • [By Keith Speights, Brian Stoffel, and George Budwell]

    Healthcare is changing rapidly. Which companies will emerge as the huge winners with these major changes? We asked three of our healthcare contributors to weigh in on the subject. Here’s whyAbbVie (NYSE:ABBV),Alphabet (NASDAQ:GOOGL) (NASDAQ:GOOG), Johnson & Johnson (NYSE:JNJ), and Veeva Systems (NYSE:VEEV) could represent bold bets on the future of healthcare.

  • [By Peter Graham]

    Mid cap global life sciencescloud-based software solutions stock Veeva Systems Inc (NYSE: VEEV) reported fiscal Q1 2018 earnings after the market closed yesterday with earningsbeating expectations. Total revenuesincreased 32% to$157.9 million as subscription services revenues rose 33% to $127.3 million whilenet incomeincreased 57% to $36.0million. The CEO commented:

  • [By Jim Crumly]

    Cloud software vendor Veeva Systems (NYSE:VEEV) has had some extraordinary success selling its products to companies in the life sciences. It is now preparing to extend its reach into other industries, and long-term investors should be excited about the potential for the long runway of growth that could result.

Top 5 Medical Stocks To Buy Right Now

Amicus Therapeutics, Inc. (NASDAQ: FOLD) is watching its shares drop on Tuesday after the company provided an update on its regulatory pathway for its Fabry Disease treatment. After the company had several collaborative discussions with the U.S. Food and Drug Administration (FDA), Amicus plans to collect additional data on gastrointestinal (GI) symptoms in Fabry patients who have an amenable mutation.

During its review of the briefing document submitted and in discussions with Amicus, the FDA acknowledged that significant unmet medical need exists in Fabry disease. The agency also indicated that kidney globotriaosylceramide (GL-3) is currently not considered a basis for an accelerated approval.

More than 50% of patients with Fabry disease report or show GI signs and symptoms, including diarrhea, abdominal pain, constipation, nausea, and vomiting. Amicus previously presented positive GI data in a completed Phase 3 randomized, placebo controlled Study 011 (FACETS) in treatment-na茂ve Fabry patients with amenable mutations.

Top 5 Medical Stocks To Buy Right Now: ManpowerGroup(MAN)

Advisors’ Opinion:

  • [By Lisa Levin] Related TRST Earnings Scheduled For October 21, 2016 Major Accounting Changes Are Coming To The Financial Industry
    Related MORN One Of The World's Most Powerful Women, Fidelity Personal Investing President Kathleen Murphy, To Tell Her Story At The Benzinga Global Fintech Awards The 2017 Benzinga Global Fintech Awards Will Include An 'Unprecedented Group' Of Judges Morningstar Packs Conference Lineup For Financial Advisors (Investor’s Business Daily) Companies Reporting Before The Bell
    Rockwell Collins, Inc. (NYSE: COL) is estimated to report quarterly earnings at $1.31 per share on revenue of $1.33 billion.
    General Electric Company (NYSE: GE) is expected to report quarterly earnings at $0.17 per share on revenue of $26.46 billion.
    Honeywell International Inc. (NYSE: HON) is estimated to report quarterly earnings at $1.60 per share on revenue of $9.32 billion.
    Interpublic Group of Companies Inc (NYSE: IPG) is expected to report quarterly earnings at $0.03 per share on revenue of $1.76 billion.
    Schlumberger Limited. (NYSE: SLB) is estimated to report quarterly earnings at $0.26 per share on revenue of $7.02 billion.
    SunTrust Banks, Inc. (NYSE: STI) is expected to report quarterly earnings at $0.83 per share on revenue of $2.21 billion.
    ManpowerGroup Inc. (NYSE: MAN) is projected to report quarterly earnings at $1.11 per share on revenue of $4.68 billion.
    Kansas City Southern (NYSE: KSU) is estimated to report quarterly earnings at $1.15 per share on revenue of $593.82 million.
    Stanley Black & Decker, Inc. (NYSE: SWK) is projected to report quarterly earnings at $1.19 per share on revenue of $2.74 billion.
    WABCO Holdings Inc. (NYSE: WBC) is estimated to report quarterly earnings at $1.44 per share on revenue of $721.89 million.
  • [By Bryan Murphy]

    Look out ManpowerGroup Inc. (NYSE:MAN). And Robert Half International Inc. (NYSE:RHI)? You may want to look over your shoulder as well. A young-and-hungry staffing solutions competitor named Staffing 360 Solutions Inc (NASDAQ:STAF) is coming on strong, and just proved it again today. Some of its preliminary fiscal Q2 numbers were reported today, and they extend what’s become a long-term growth streak.

    The definition of a roll-up isn’t a hard and fast one, though even the broad brush strokes paint a pretty clear picture. Investopedia defines a roll-up (also known as a “roll up” or a “rollup”) a merger that occurs when investors (often private equity firms) buy up companies in the same market and merge them together. Roll-ups combine multiple small companies into something bigger and better to be able to enjoy economies of scale. Private equity firms use roll-ups to rationalize competition in crowded and/or fragmented markets and to combine companies with complementary capabilities into a full-service business.

    It’s also the kind of strategy Staffing 360 Solutions is executing, with great success. For the fiscal quarter ending in November, Staffing 360 Solutions has pre-reported revenue of $47 million, and a gross profit of $8.1 million. Those figures are up 14% and 8%, respectively, year-over-year.

  • [By Bryan Murphy]

    Staffing agencies like Robert Half International Inc. (NYSE:RHI) and ManpowerGroup Inc. (NYSE:MAN) may want to look over their shoulder. Though both are bigger and more established, their size and the waning need for physical, human workers in an increasingly-digital and roboticized world ultimately works against both organizations. That paradigm shift doesn’t matter much to a young, up-coming-staffing agency called Staffing 360 Solutions Inc (NASDAQ:STAF) though. Indeed, the trend of computer-based everything leaves Staffing 360 Solutions in the proverbial cat-bird’s seat. Its fiscal Q2 numbers verify the company is in the right place at the right time.

    Those numbers? Revenue of $47.1 million was up 14%, and gross profits of $8.1 million were higher by 8.4% on a year-over-year basis. Moreover, the net loss of $1.5 million was a marked improvement on the year-ago loss of $3.5 million, and the EBITDA of $1.4 million was about the same. Operating expenses fell from 22% of revenue a year earlier to only 17% last quarter, with more such progress on the way.

    Perhaps most important, Staffing 360 Solutions saw organic growth of 7%, meaning the top line bumped up by that much not because of acquisitions, but because it’s existing divisions expanded their client base and billings by 7%.

    And last quarter’s progress has been the norm for several quarters now.

    While STAF is proving outpacing the growth from bigger names like ManpowerGroup and Robert Half International, it can’t come as a complete surprise. Staffing 360 Solutions is focused on the IT sliver of the staffing industry, connecting companies with the technology-skilled programmers, cybersecurity specialists, and computer networking personnel modern organizations increasingly need.

    There are several data nuggets that point in the same direction, but perhaps none as telling as a recent conclusion from technology research outfit IDC speaks volumes. IDC believes that by the

Top 5 Medical Stocks To Buy Right Now: Novellus Systems Inc.(NVLS)

Advisors’ Opinion:

  • [By Paul Ausick]

    Nivalis Therapeutics Inc. (NASDAQ: NVLS) dropped 60% on Tuesday to post a new 52-week low of $2.50 after closing at $6.25 on Monday. The stock’s 52-week high is $9.45. Volume of about 4.2million was about 60 times the daily average of around 75,000 shares. The company reported a failed mid-stage trial on its treatment for cystic fibrosis.

  • [By Lisa Levin]

    Nivalis Therapeutics Inc (NASDAQ: NVLS) shares dropped 59 percent to $2.58 after the company reported it failed to demonstrate benefit in absolute change in predicted FEV1 or in Sweat Chloride Reduction at 12 weeks. The failed trial has prompted four Wall Street firms to downgrade the issue including Raymond James, Cowen, Baird and Stifel.

  • [By Chris Lange]

    Nivalis Therapeutics, Inc. (NASDAQ: NVLS) is watching its shares crumble on Tuesday after the company gave an update on its mid-stage Cystic Fibrosis (CF) trial. Specifically, the company announced topline results from the its Phase 2 trial evaluating the efficacy and safety of two doses of cavosonstat, in adult patients with CF who had two copies of the F508del-CFTR mutation and were being treated with Orkambi.

Top 5 Medical Stocks To Buy Right Now: RPX Corporation(RPXC)

Advisors’ Opinion:

  • [By Travis Hoium]

    Shares of risk management company RPX Corp. (NASDAQ:RPXC) popped as much as 15% in trading Wednesday after buyout rumors started to swirl in the market. At 2:55 p.m. EST, shares had settled down to an 11.2% gain on the day.

Top 5 Medical Stocks To Buy Right Now: Santander Consumer USA Holdings Inc.(SC)

Advisors’ Opinion:

  • [By Jim Robertson]

    On Friday, our Under the Radar Moversnewsletter suggested going long on small cap consumer financestock Santander Consumer USA Holdings (NYSE: SC):

  • [By Wayne Duggan]

    Height Financial Services analyst Edwin Groshans believes Credit Acceptance Corp, Santander Consumer USA Holdings Inc (NYSE: SC), Ally Financial Inc (NYSE: ALLY) and Capital One Financial Corp. (NYSE: COF).

Top 5 Medical Stocks To Buy Right Now: NCI Building Systems, Inc.(NCS)

Advisors’ Opinion:

  • [By Scott Rubin]

    Equity gainers on the day included Chico's FAS, Inc. (NYSE: CHS), which surged more than 12 percent on the day, and Himax Technologies (NASDAQ: HIMX), which climbed almost 9 percent in the wake of an afternoon rally. Losers included NCI Building Systems Inc. (NYSE: NCS), which fell 15 percent after earnings, and H&R Block inc (NYSE: HRB), which fell almost 11 percent on the day after its Q1 results.

  • [By Lisa Levin]

    NCI Building Systems Inc (NYSE: NCS) was down, falling around 14 percent to $15.27. NCI Building Systems reported Q3 adjusted earnings of $0.33 per share on revenue of $462.4 million.

  • [By Monica Gerson]

    NCI Building Systems Inc (NYSE: NCS) posted upbeat results for its second quarter on Tuesday. NCI Building Systems shares rose 1.24 percent to $16.30 in the after-hours trading session.

  • [By Jim Robertson]

    Yesterday, small cap NCI Building Systems (NYSE: NCS) sank 20.54% after the maker of metal products for the nonresidential building industry reported disappointing Q3 results and cut its sales outlook. NCI Building Systems is one of North America’s largest integrated manufacturers and marketers of coatings, components and metal buildings for the nonresidential building industry and is comprised of a family of companies operating manufacturing facilities across the United States, Canada, Mexico and China (with additional sales and distribution offices throughout the United States and Canada).

Cal-Maine Foods – Naysayers Have Missed Recent Stock Price Surge

Source: Google Images


I am fascinated with commodities. This is why I invest in companies like Cal-Maine Foods (CALM), Sanderson Farms (SAFM), Bunge Limited (BG), Hormel Foods (HRL), Fresh Del Monte (FDP), and oh yea, Concho Resources (CXO), Pioneer Natural Resources (PXD) and Rice Midstream Partners (RMP).

But it is very important to follow indicators impacting companies with exposure to commodities. For companies like Cal-Maine, Hormel and Sanderson, this relates to their produced products, as well as their cost inputs. Others may be more sensitive to core produced supply and demand trends.

Cal-Maine has been a challenging company to both analyze and invest in. All commodities go through up and down cycles. For shell eggs, the recent avian influenza outbreak during 2015 led to an extreme loss of hen laying egg production, concurrently leading to higher egg prices and substantially stronger net sales and profits for Cal-Maine.

Since the peak in the fall of 2015, Cal-Maines stock price has been under pressure as hen egg laying production ramped back up, inventories peaked and egg prices plummeted. This translated to a 43-percent stock price decline from Cal-Maines October 2015 peak at $61 to the August 2017 low-point above just above $34.

In the spring of 2017, analysts were calling for Cal-Maines stock price to be fairly valued in the low $30s to even below the $30 per share mark. This was expressed by both Goldman and Cleveland Research. Since this time, I have been assessing factors for Cal-Maines business (laying hen growth, chicken hatcheries, retail demand, inventory builds and national and regional pricing). The most important variable for Cal-Maines stock price continues to be egg price movements. The challenge has been as to the predictability of where prices may be headed.

Through the summer and fall, Seeking Alpha contributors have largely expressed muted to negative tones for Cal-Maines prospects. But the negative tone from the spring through the fall has led to missing a strong stock price rally for Cal-Maine.

In fact, Cal-Maines stock price is now up over 31 percent since the spring. For investors, the important question is why did analysts and the Seeking Alpha community miss this opportunity? I was not necessarily as bearish, but I was also not anticipating such a rise myself. My only core difference of opinion was that as seasonality played a factor into the holidays, that pricing would again rise, leading to a correlation in Cal-Maines stock price appreciating.

Looking to the near-term, I do see much better days ahead, notably, a reinstated dividend. There are many who believe that the recent economic cycle is facing imminent collapse. I am of the opinion that we still have a few innings left for inflation to rise and the economy to accelerate growth further. As such, Cal-Maine may see sustained egg price increases based on supply and demand improvements leading to a higher fair value.

Supply & Demand

The chart above is my quick-and-dirty go to chart for supply and demand. Ultimately, egg prices are the most important factor for Cal-Maines business. The higher the prices, the more net sales per processed and sold dozens, and the higher the profit margin. This chart provides daily southeast large egg prices against Cal-Maines stock price.

There have been varying times where Cal-Maines stock price has been near or at parity with egg prices, but regardless, the correlation between the two is clear. Since the summer of 2017, parity has been much closer.

On the demand side, performance for 2017 has been robust versus the previous few years. Through November 24th, national retail shell egg purchases were up 5.5 percent from last year. Over the last four years, performance was at -0.3, -0.3, 2.9 and -3.6 percent. The combination of lower egg prices from 2016 and 2017, combined with an improving economy has likely led to higher consumer demand.

For inventories, conventional egg build has been at a slower pace versus demand through November. Inventory across the nation was up just below 3 percent, with the Southeast region witnessing an increase above 15 percent.

Laying hen information has also been on the decline when comparing year-over-year (YoY) percentage changes for the number of laying hens, eggs per 100 layers and the number of eggs produced. These measures appear to be approaching more historical pre-avian influenza levels.

Fair Valuation

Source: Transports In Focus

My discounted cash flow (DCF) valuation is over a five-year period to Cal-Maines fiscal year 2021. It is based on Cal-Maines shell egg sales (dozens sold and net average selling prices) and non-shell egg sales estimates for net sales. And it is based on estimates for feed and other costs per dozen for farm production, and other cost of sales items and selling, general and administrative expenses (SG&A).

I am modeling Cal-Maine to grow net sales by an average of nearly 12 percent to $1.9 billion by fiscal year 2021, with the companys operating margin gradually improving to 12 percent. I am factoring for increasing farm production costs versus todays declining environment (corn and soybean meal). The tax rate is stable at 35 percent to derive Cal-Maines net operating profit after tax (NOPAT).

After factoring for non-cash adjustments and working capital and capex, I have Cal-Maine modeled to generate $310 million in unlevered free cash flow through this period in net present value. My cost of capital is assumed at 6.5 percent, the EBITDA multiple is assumed at 7 times, and the future cash flows growth rate is assumed at 2.5 percent.

Compared to analyst average price targets ($40.33), the EBITDA method reflected a 4 percent premium. Based on the perpetuity method, the premium is closer to 50 percent. Today, Cal-Maines stock price trades at nearly $50 per share; an 18 percent premium to the EBITDA method, and a 19 percent discount to the perpetuity method.


Investors need to remember that commodity stocks are highly volatile. I am assuming increasing feed costs near mid-single digits for the majority of the five-year period. My stance is that inflation is likely to accelerate over the next few years, which will be positive for most commodity sectors and industries.

This scenario has played out nicely for Sanderson, which is up greater than 80 percent for the companys fiscal year. With only one quarter in the bag for fiscal year 2018, Cal-Maine is already up over 30 percent. Some of this can be attributed to seasonality, but this type of performance was not expected by analysts and many here on Seeking Alpha.

My buys into Cal-Maine were by no means perfect, but were very timely during October 2016 and April 2017, with an average cost basis below $39. As is the case in most commodity cycles, patience is typically rewarded. Upside potential may be a moving target to a degree, but when it hits, it tends to lead to rapid stock price appreciation.

For Cal-Maine to head towards, and eventually eclipse the $60 per share mark, the inflation and acceleration of economic growth scenario will need to play out. Keeping apprised of supply and demand indicators is a must egg export markets may be an added tipping point for the near-term.

Disclosure: I am/we are long CALM, BG, SAFM, HRL, FDP, CXO, PXD, RMP.

I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

About this article:ExpandAuthor payment: $35 + $0.01/page view. Authors of PRO articles receive a minimum guaranteed payment of $150-500.Tagged: Investing Ideas, Long Ideas, Consumer Goods, Farm ProductsWant to share your opinion on this article? Add a comment.Disagree with this article? Submit your own.To report a factual error in this article, click here